Mylan Can't Launch Doryx Generic Just Yet

Law360, New York (February 8, 2012, 7:08 PM EST) -- A New Jersey federal judge on Wednesday blocked Mylan Pharmaceuticals Inc. from launching a generic version of Warner Chilcott PLC’s anti-acne medication Doryx.

U.S. District Judge William J. Martini issued a temporary restraining order, with the agreement of both parties, in order for the court to complete the impending trial, consider the evidence and render a decision.

Mylan had sought to market a generic version of the Doryx 150-milligram doxycycline hyclate delayed-release tablet products, according to the suit.

Judge Martini also issued an identical TRO in...
To view the full article, register now.